ARMATA PHARMACEUTICALS, INC. Debt Conversion, Converted Instrument, Amount
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Debt Conversion, Converted Instrument, Amount of $955.00 thousand for the 9-month period ending 2014-09-30, per its 10-Q/A filed 2015-04-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2015-04-15
- ARMATA PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2014-09-30 was -$382.00K.
- ARMATA PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2014-06-30 was $1.34M, a 116.34% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2014-03-31 was $0.00.
- ARMATA PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2013-12-31 was $5.70M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2014-09-30 | -$382.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2015-04-15 | $955.00K derived: sum of 2 quarters · filed 2015-04-15 | $955.00K 10-Q/A · filed 2015-04-15 | $6.65M derived: sum of 4 quarters · filed 2015-04-15 |
| 2014-06-30 | $1.34M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2015-04-15 | $1.34M 10-Q/A · filed 2015-04-15 | $7.04M derived: sum of 3 quarters · filed 2015-04-15 | $7.04M derived: sum of 4 quarters · filed 2015-04-15 |
| 2014-03-31 | $0.00 10-Q/A · filed 2015-04-15 | $5.70M derived: sum of 2 quarters · filed 2015-04-15 | $5.70M derived: sum of 3 quarters · filed 2015-04-15 | $6.32M derived: sum of 4 quarters · filed 2015-04-15 |
| 2013-12-31 | $5.70M derived: 10-Q/A 12 month − 10-Q/A 9 month · filed 2015-04-15 | $5.70M derived: sum of 2 quarters · filed 2015-04-15 | $6.32M derived: sum of 3 quarters · filed 2015-04-15 | $6.32M 10-Q/A · filed 2015-04-15 |
| 2013-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2015-04-15 | $618.00K derived: sum of 2 quarters · filed 2015-04-15 | $618.00K 10-Q/A · filed 2015-04-15 | |
| 2013-06-30 | $618.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2015-04-15 | $618.00K 10-Q/A · filed 2015-04-15 | ||
| 2013-03-31 | $0.00 10-Q/A · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |